GSK raised its 2025 sales and earnings forecasts due to growth in HIV and cancer drugs, boosting shares by 7%. Despite strong performance, challenges remain in the U.S. vaccine market.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
GSK cancer, HIV drug sales lift 2025 outlook in boost for shares
